Mid-Morning Look: February 15, 2022

Auto PostDaily Market Report

Mid-Morning Look

Tuesday, February 15, 2022

Index

Up/Down

%

Last

 

DJ Industrials

387.92

1.12%

34,954

S&P 500

53.64

1.22%

4,455

Nasdaq

216.62

1.57%

14,005

Russell 2000

35.49

1.76%

2,056

 

 

U.S. stocks rally with today’s focus remaining on the prospect of de-escalation on the Ukraine border after Russia’s Defense Ministry said it had pulled back some troops from near Ukraine, instead of higher wholesale prices as the January producer-price index (PPI) comes in near record highs and well above economist estimates. Futures jumped more than 1% overnight (holding gains thus far) on reports Russia announced a pullback of forces on the Ukraine border amid a new round of shuttle diplomacy. The news boosted U.S. stocks while sunk oil prices (which jumped to fresh 7-year highs yesterday on news of increased tensions) and gold prices as traders bailed on safe-haven assets. Treasury yields resumed the upward climb with the 10-year back above 2.04%. Meanwhile, inflation showing no signs of easing up after the January PPI came in at 1% m/m, more than double estimates while y/y rose 9.7%, just shy of its record high of +9.8%, while rising on a core basis as well. The S&P 500 at a crucial level after the overnight spike, trading back near its 200-day moving average level around 4,454.

 

Economic Data

·     Producer Price Index (PPI) for January shows headline and core readings “hotter” than expected – PPI headline m/m rises +1.0% vs. est. +0.5% and headline y/y rises +9.7% vs. est. +9.1%; on a core basis (ex food & energy) Jan PPI rises +0.8% m/m vs. rest. +0.5% and rises +8.3% vs. est. $7.9% y/y

·     Empire state current business conditions index +3.1 in February vs -0.7 in January; new orders index +1.4 in February vs -5.0 in January; prices paid index +76.6 in February vs +76.7 in January; employment index at +23.1 in February vs +16.1 in January; and the six-month business conditions index +28.2 in February vs +35.1 in January

 

 

Macro

Up/Down

Last

 

WTI Crude

-4.54

90.92

Brent

-4.32

92.17

Gold

-17.40

1,852.00

EUR/USD

0.0029

1.1335

JPY/USD

0.24

115.77

10-Year Note

0.042

2.038%

 

 

Sector Movers Today

·     Retailers; GPS downgraded underperform from Neutral at bank America and cut tgt to $14 from $26 as expect Old Navy (55% of sales) to be disproportionately hurt by its exposure to the low-income consumer and by worsening supply chain challenges which puts estimates at risk: our 1H22E and FY22E EPS estimates are 28% and 16%; Cowen said in department stores, its top pick is Macy’s (M) given greater upside potential on category strength, merch margins, and digital innovation as see 4Q21 EPS of $1.99 vs the Street’s $1.96, primarily driven by a slightly higher sales outlook and expense leverage (also lowers JWN tgt to $25 from $27); KSS unveils locations of 400 new Sephora at kohl’s shops opening this year; WHR raises quarterly dividend 25%, raises share repurchase plan by $2B

·     Utilities & Solar rise; UBS upgraded HASI to Buy given its attractive valuation and relatively stable underlying earnings, CNP to Buy as it trades in-line with average regulated utilities valuation despite being one of the fastest growing utilities with a misunderstood ESG position, and SPWR to Neutral on a more balanced risk/reward with shares having declined 68% since its Jan. 2021 peak, while downgrading NI to Neutral after its outperformance over the past 6 months has pushed the stock to price in its above-average EPS growth; Bank of America double-upgraded DTE to Buy from Underperform after last week’s earnings report included an FY21 beat on already raised guidance, a raise of its FY22 EPS range, and strong affirmation of its long-term growth trajectory; ARCH Q4 EPS $11.92 vs est. $12 on revenue $805.7M vs est. $691.5M, plans to relaunch cap return program in Q2 with 50% of discretionary cash flow being returned to shareholders via a variable dividend on top of its current 25c/shr dividend and the remaining 50% retained for buybacks, special dividends, and capital preservation

·     Consumer Finance; ADS reported delinquencies for January of 4.2% vs. 4.3% y/y, while delinquencies were 4.2% vs. 4.3% y/y; COF reported charge-offs for January of 2.03% vs. 2.54% y/y and delinquencies at 2.4% vs. 2.49% y/y; DFS reported charge-offs for January of 1.76% vs. 2.57% y/y and delinquencies 1.75% vs. 2.08% y/y; SYF reported charge-offs for January of 2.05% and delinquencies 1.49%; reported charge-offs for January of 1.02% and delinquencies 0.7%; MA said expands consulting with practices dedicated to crypto, open banking and ESG

·     Pharma movers; IMGN announced a license agreement with LLY of its Novel Camptothecin ADC Platform for up to $1.7 billion in potential payments; IMGN will receive $13 million upfront and up to $32.5 million for meeting certain milestones; ZTS 4Q adj EPS $1.00 vs est. $0.96 on revs $2.0B vs est. $1.9B; guides FY22 revs $8.325-8.475B vs est. $8.41B and adj EPS $5.09-5.19 vs est. $5.21; AZN said that a Phase 3 trial of Lynparza plus abiraterone showed that the drug combination reduced risk of disease progression in patients with prostate cancer

 

Stock GAINERS

·     ANET +5%; delivered positive results and outlook as sales beat +4%, EPS beat by +11% and the March quarter guidance for +27% y/y sales growth is also +2% better than expectations and guided to 1Q22 operating margin of 38% vs. est. 37%

·     CCL +6%; as airlines and cruise names (reopen plays) outperform early

·     MGI +19%; enters into agreement to be acquired by Madison Dearborn Partners for $11.00 per share in cash to accelerate advancement of digital growth strategy in a deal valued at $1.8B including debt https://on.mktw.net/3LDJHVu

·     MNST +2%; Bloomberg reported last night merger talks between MNST and STZ are progressing, and a merger agreement could be reached in the coming weeks if negotiations proceed smoothly https://bloom.bg/3Bp8rMt

·     QSR +4%; reported Q4 profit and revenue that rose above expectations, as Burger King same-stores sales beat forecasts to help offset misses by Tim Horton’s and Popeyes Louisiana Kitchen

·     RESN +249%; filed an 8-K announcing its definitive agreement to be acquired by Murata for $4.50/share in an all-cash transaction worth ~$285mn in enterprise value as the deal represents a ~266% premium to RESN’s closing price of $1.23

·     SABR +19%; Q4 adj EPS (47c) loss wider than est. (45c) on revs $500.6M vs est. $497.1M, its FY22 guidance is dependent on bookings recovery, but if bookings recover 50% the midpoint of FY22 total revs guidance range $2.4-2.7B

·     SE +6% after tumbling -18% Monday after India has banned 54 new apps, including SE’s game Free Fire

·     SPWR +5%; upgraded to Buy in the solar space at UBS; seeing broad strength with ENPH among top S&P leaders

·     TSEM +41%; as INTC confirmed a prior WSJ report overnight as it acquires Israeli chip company Tower Semiconductor (TSEM) for almost $5.4B, paying $53 per share

 

Stock LAGGARDS

·     CAR -14%; posted strong quarterly results, but shares move lower

·     CIEN -3%; guides Q1 revs $840M-$850M vs. est. $895M and sees Q1 gross margins 44%-45%; continue to see an unprecedented level of demand for our products and services and continue to expect to achieve our revenue guidance of 11% to 13% annual growth

·     CYTK said data from late-stage study showed its experimental treatment, omecamtiv Mecarbil, had no effect on exercise capacity in patients with a type of heart failure

·     FIS -7%; after Q4 EPS and revs missed estimates and guided Q1 EPS $1.44-$1.47, below the $1.56 estimate and revs also falling short of consensus $3.42B-$3.45B vs. est. $3.49B

·     INTU-2%; after saying expects Q2 revenue to reflect slower forming tax season as sees $2.66B-$2.665B below prior $2.71B-$2.75B due to a slower forming tax season

·     IPGP -9%; after weaker guidance as sees Q1 revenue $320M-$350M below est. $370M and EPS 85c-$1.15, below estimate $1.32 – trades at 52-week lows

·     LEGN -3%; after the FDA places clinical hold on the co’s lymphoma trial

·     LRMR -62%; says the FDA is maintaining its clinical hold at this time on Larimar’s CTI-1601 program and that additional data is needed to resolve the clinical hold

_________________________________________________________________

Market commentary provided by Hammerstone Markets, Inc, a firm separate from and not affiliated with Regal Securities. Regal Securities has not participated in the creation of the content, and does not explicitly or implicitly endorse the content.

Live Trading

Open an Account

Paper Trading

Register